Bullfrog AI Holdings, Inc. Common Stock (BFRG) vs Citius Pharmaceuticals, Inc. (CTXR)
A side-by-side comparison of Bullfrog AI Holdings, Inc. Common Stock and Citius Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BFRG
Bullfrog AI Holdings, Inc. Common Stock
$0.69HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
CTXR
Citius Pharmaceuticals, Inc.
$0.48HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BFRG vs CTXR
growth of $100 · dividends reinvested · last 4yBFRG -90.9% (-45.0%/yr)CTXR -98.5% (-65.1%/yr)BFRG compounded faster over this window
Log scale — wide-divergence pair
BFRG CTXR
BFRG vs CTXR: by the numbers
- •CTXR is the larger company ($13M vs $13M market cap).
- •Both run net losses; CTXR's is the smaller (-651.27% vs -2006.87% net margin).
Metrics side by side
Valuation
| Metric | BFRG | CTXR |
|---|---|---|
| P/S ratio | 42.76 | 1.86 |
| P/B ratio | 1.83 | 0.20 |
Profitability
| Metric | BFRG | CTXR |
|---|---|---|
| Gross margin | 18.76% | 0.00% |
| Operating margin | -5652.38% | 0.00% |
| Net margin | -2006.87% | -651.27% |
| ROE | -85.82% | -69.47% |
| ROIC | -86.22% | -67.62% |
Growth (annualized)
| Metric | BFRG | CTXR |
|---|---|---|
| Total return CAGR (5Y) | N/A | -60.04% |
Go deeper
Dig into the metrics
Bullfrog AI Holdings, Inc. Common Stock ROECitius Pharmaceuticals ROEBullfrog AI Holdings, Inc. Common Stock operating marginCitius Pharmaceuticals operating marginBullfrog AI Holdings, Inc. Common Stock revenue growthCitius Pharmaceuticals revenue growthBullfrog AI Holdings, Inc. Common Stock free cash flowCitius Pharmaceuticals free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.